👉 So… is it time to trash hydralazine #NephJC? 🗑️
#TenPostNephJC #NephSky #medsky
➡️ Up next (05/06/26): TRPC6 inhibition in FSGS, a phase 2 trial of BI 764198
pubmed.ncbi.nlm.nih.gov/41616795/
Join us www.nephjc.com
Nice blog post about the various milk options and what they offer kidney patients:
www.medscape.com/viewarticle/...
Happy to see our commentary with @jbrianbyrd.bsky.social suggesting that Angiotensin II should be part of the evaluation of primary hyperaldosteronism. @nu-nephrology.bsky.social @nufeinbergmed.bsky.social
www.ahajournals.org/doi/10.1161/...
Renalism: The failure to perform appropriate diagnostic/ therapeutic interventions in patients with CKD due to concern about risk of AKI #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/15339996/
PISCES VA
And the causes of death are heart failure, sudden death, infections- how would fish oil impact those in such a huge way?
It is all a bit puzzling
See @nephroseeker.medsky.social beautiful VA till then
#KidneyWk
Yeah - fish oil having such a huge effect is a bit odd. We will be going deep into it on a future #NephJC to understand this.
Dialysis is tricky - statins don’t work as well, beta-blockers perhaps do, and the pathophysiology is different.
#NephJC #KidneyWk
Missing all the overwhelming amount of science coming out of #KidneyWk?
The #NephJC crew has got you covered
Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi
LBRO
And in the evening
- a CAR T in refractory SLE
- a PKD trial
- increasing PD in Vets
- Povetacicept in IgA
- TESTING Longterm term data
- what do the AHA/ACC BP guidelines mean?
#KidneyWk
LBCT session
Today’s LBCTs and late breaking science!
Morning:
- an Alport trial!
- Telitacicept
- REGENCY biopsy data
- Vitamin R updated in Membranous
- another sibeprenlimab slice
- Balcinrenine + Dapa in CKD
#KidneyWk
Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk
Simultaneous pub in NEJM
www.nejm.org/doi/full/10....
Was listening to nephjc freely filtered episode of ACHIEVE trial just the other day. Of all the things we've tried in HD and failed, and now fish oil does the trick??? @kidneyboy.bsky.social @hswapnil.medsky.social
It’s 2025 and we’re still dosing drugs like it’s 1976.
The saga of Cockcroft–Gault, FDA inertia, and the slow evolution of renal dosing equations.
🧮 pbfluids.com/2025/10/cock...
🚀🖥️ The @nikttaskforce.bsky.social Dashboard Prototype is Live!
🔗 Explore it here: www.niktt.com.au/data-dashboard
📢 We would like to know what you think-please provide feedback here: forms.cloud.microsoft/pages/respon...
📌 Note: The dashboard is best viewed on a desktop computer
should we screen for CKD in the general population?
Finally, flozins, finerenone and GLP1s allow a good cost-effectiveness case
www.nephjc.com/news/2025/7/... for #NephJC shorts
Time to stop just being dialysis-ologists and flozinate, glipinate!
#NephSky
Algorithmic approach to Peritoneal Dialysis (PD) Catheter OUTFLOW FAILURE
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/20630641/
CKD-MBD still undefeated in its ability to generate negative trials!
This study sounds like a three-foot putt. How can sevelamer not be better at reducing propensity toward calcification? I don't know but P=0.8.
HELLO I HAVE A ROUTINE CONSULT THEY CAN BE SEEN IN THE MORNING JUST WANNA LET YOU KNOW ABOUT IT NOW AT MIDNIGHT OKAY THANKS GOODNIGHT
consulted for a potassium of 5.5 on a patient who recently started both entresto and aldactone. i am a salieri in a world with no mozarts.
Work smarter, not harder!
A low renin with concurrent use of ACEi/ARB is almost certainly some shade of Primary Aldosteronism.
Either way, aldosterone-directed therapy is very likely to provide major clinical benefits
www.ahajournals.org/eprint/TUS6C...
FRESH-UP Trial #ACC25 #medsky
RCT comparing liberal vs restricted fluid intake (≤1500 ml/d) in 504 pts with stable chronic HF
🌊No difference in status health quantified by Kansas City Cardiomyopathy Questionnaire at 3 mths
🌊 More thirst distress with restriction
www.nature.com/articles/s41...
People look at this and scream about getting an AV accesses because of the dramatically lower infection rate, but 1.2 infections per 100 patient-years is 1.2 blood stream infections per patient per 8.8 years
We have bigger fish to fry in dialysis than one BSI per decade.
Survival analysis
Tables with actual event rates
The oral sema results are interesting
Difficult to comment indirectly, but seems less impressive than injectable sema?
Lot of kidney and HF events and favourable point estimates but not a huge effect
#ACC25
Although I suppose that the newly published meta-analysis is the counterpoint.
Starter packs may be passé - but we have had an influx, and we now have a 1/3rd full 6th nephrology pack
5th pack go.bsky.app/JJ4h8su
4th pack: go.bsky.app/YeuH82
3rd pack: go.bsky.app/2yLiYN4
2nd pack go.bsky.app/N27Kzri
1st pack: go.bsky.app/H4td28C
6th go.bsky.app/Gsm6BeJ
#NephSky
Also note two large RCTs ongoing - or about to start - in France: bsky.app/profile/dgue...
We also recently transitioned a pt to both - incremental HDF 💧💦 Some are very CONVINCEd in our dept but we may INCH closer to finding an answer #AKTN aktn.org.au/inch-hd/ pubmed.ncbi.nlm.nih.gov/36938090/ @sarahkmels.bsky.social @nephmadness.bsky.social
#Quiz: A man in his 40s with untreated hypertension presented with right-sided neurologic deficits and slurred speech. His hypertension & age prompted investigation for a secondary etiology of his hypertension. What is the differential diagnosis?
bit.ly/3gyO2ie (FREE)
>50% of Nephrologists in the US are foreign graduates, likely many not US citizens. It's one of most cognitively complicated specialties in medicine, and not paid well enough for amount of work involved for many US grads. Good luck caring for aging US population when deporting >50% of your doctors